Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
16.24
+0.50 (3.18%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Kailera Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Kailera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $42.4. The average 1-year stock price forecast is 161.08% higher than the current stock price, while the lowest is $30 (+84.73%) and the highest is $57 (+250.99%).
Price Target: $42.4 (+161.08%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kailera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $48 | Buy | Maintains | $48 | +195.57% | Aug 14, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $30 | Buy | Maintains | $30 | +84.73% | Aug 13, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $57 | Buy | Reiterates | $57 | +250.99% | Aug 13, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 13, 2026 |
| Evercore ISI | Evercore ISI | Buy Initiates n/a | Buy | Initiates | n/a | n/a | May 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.38
EPS Next Year
-4.30
from -4.38
EPS and Forward PE are based on non-GAAP adjusted numbers.